Campaign highlights unique stories and experiences of the HPP community to raise awareness CHESHIRE, Conn. October 27, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the launch of the Every Day with HPP™ campaign in support of the third annual Hypophosphatasia (HPP) Awareness Week Oct. 26–Nov. 1, 2014. HPP Awareness Week is a national public […]
CHESHIRE, Conn. October 23, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers will present seven posters detailing findings from clinical studies of Soliris® (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS) as well as from the Global aHUS Registry at the annual meeting of the American Society of Nephrology (ASN), being held November […]
SOUTH SAN FRANCISCO, Calif. OCTOBER 20, 2014 – Sequenta, Inc., a biotechnology company developing clinical diagnostics based on immune cell receptor genes, today announced an equity investment by Celgene Corporation and other strategic investors. This financing, in addition to funding secured from several other strategic investors, will support incorporation of the ClonoSIGHT™ minimal residual disease […]
SOUTH SAN FRANCISCO, Calif. MAY 28, 2014 – Sequenta, Inc. today announced publication of a study done in collaboration with researchers from UCSF and UCLA that used the company’s proprietary LymphoSIGHT™ immune repertoire sequencing platform to investigate the effects of anti-CTLA-4 antibody on the number and types of T cells present in a patient’s blood. […]
SOUTH SAN FRANCISCO, Calif. MAY 22, 2014 – Sequenta, Inc. and its academic collaborators will share data about the use of the company’s next-generation sequencing-based assay for minimal residual disease (MRD) in lymphoid cancers (available clinically in the United States as the ClonoSIGHT™ test) in one oral and three poster presentations at the 19th Congress […]